Medical reform accelerated the medical circulation industry to transform the head of the head enterprise layout equipment manufacturing to find new growth points

The 21st Century Business Herald reporter Chen Hongxia Intern reported that Wuhan reported that with the rapid development of the medical device industry, the structure of the domestic medical circulation industry became stable. In the context of continuous advancement of medical insurance reform, the medical circulation industry may face a new round of transformation. At present, creating a digital supply chain and expanding market space has become the first choice for head pharmaceutical business enterprises, but there are also head pharmaceutical business enterprises began to increase their efforts to build the equipment industry business and find the second growth point.

On August 11, Rong Wenhui, assistant chairman of Kyushu Tong Medical Device Group Co., Ltd., said in an interview with the 21st Century Business Herald that Kyushu Tong (600998.SH) is stepping up the layout of the industrial product of medical device and differentiation. On the three major business lines of products, surgical sensing consumables, and rehabilitation solutions, find the blue ocean market to further enhance the market competitiveness of the group's medical device business. Especially in the latter two markets, while the current domestic products are relatively red -sea, they are becoming a new field for domestic medical device heading enterprises. The field is developed to expand the market share in the field. "

Industry entering the transition period

At present, the Chinese medical device market has developed rapidly, and the growth rate exceeds the global average growth rate. Burning Consultation predicts that the global medical device market size may exceed 800 billion US dollars in 2030, and the CAGR from 2020-2030 will be 6.3%, exceeding the growth rate of the drug industry. From 2015 to 2020, the size of the Chinese medical device market increased from 312.6 billion yuan to 778.9 billion yuan, and the CAGR was 20%. It is expected that the market size in 2030 will exceed 2.20 trillion yuan. From 2020-2030, CAGR is expected to reach 11%. Essence

In the process of rapid development of the medical device industry, the structure of the domestic medical circulation industry has stabilized. According to the data of the CSI industry classified pharmaceutical business sector, in 2021, Shanghai's pharmaceutical revenue ranked first, reaching 215.824 billion yuan; Kyushu Tong's revenue was 122.407 billion yuan, ranking second, and is my country's largest private pharmaceutical comprehensive service Business; the consistency of the Chinese medicine and the national medicine shares ranked third and fifth, with 68.358 billion yuan and 62.521 billion yuan, respectively; Heavy Pharmaceutical Holdings was fourth, achieving revenue of 46.469 billion yuan. In addition, Hong Kong -listed companies, which are also located in the pharmaceutical business industry, and China Pharmaceutical Holdings and China Resources Pharmaceutical's revenue were 521.051 billion yuan and 193.613 billion yuan, respectively.

However, with the continuous advancement of medical insurance reform, the medical circulation industry may face a new round of transformation. The annual report of Chinese Medicine Holdings 2021 shows that the intensive implementation of medical reform policies such as “Biabinglaering”, “National Medical Insurance negotiations”, and “paying according to disease” not only caused the decline in the price of medicine and abalment, the slowdown in traditional business, and the pressure of gross profit margin, etc. A series of industry challenges will also comprehensively promote the transformation and distribution mechanism of the industry's service needs, stimulate a new market competition pattern and diversified innovation and development opportunities.

Compared with 2020, the gross profit margin of domestic medical business enterprises has declined to varying degrees. The sales gross margin of Chinese Medicine Holdings, Shanghai Pharmaceutical, China Resources Pharmaceutical, and Kyushu Tong were 8.45%, 13.23%, 14.94%, and 8.04%, respectively, a year -on -year decrease of 0.38%, 1.07%, 1.17%, and 0.93%.

At present, creating a digital supply chain and the expansion of the market has become the only way for head pharmaceutical business enterprises. In 2021, China Resources Pharmaceuticals implemented a regional development strategy in terms of pharmaceutical distribution business, improved the integrated management of supply chain, expanded product category and upstream resources, promoted digital transformation and upgrading, layout of new Internet medical services for the Internet, strengthened the professional capabilities of equipment distribution business, Essence

Sinopharm control has also continued to increase digital and intelligent transformation investment. In the four formats of drugs, equipment, retail, and logistics, the construction of digital transformation projects is simultaneously carried out. Professional national integrated services "transformation and upgrading. At the same time, Kyushu Tong said, "In 2022, the company will create a new type of digital pharmaceutical circulation model by establishing a new pharmaceutical industry supply chain platform."

Looking for the blue ocean market

While optimizing the supply chain, head pharmaceutical business enterprises have begun to increase their efforts to build independent brands and find the company's second growth point.

In recent years, Kyushu's strategy has been adjusted. Rong Wenhui introduced, "While the company develops the main business of the commercial sector, the industrial owner's own products and medical services are the two businesses that the company is layout. The industrial business can help the company increase the value." Equipment Group Co., Ltd. (hereinafter referred to as "Kyushu Tong Equipment Group"), which is a wholly -owned subsidiary established by Kyushu in 2012. From 2017 to 2021, the sales of Kyushu Tong Equipment Group were 7.25 billion yuan, 13 billion yuan, 17.3 billion yuan, 23.7 billion yuan, and 26.9 billion yuan, respectively.

Relatively speaking, industry companies that "switch" in the pharmaceutical industry from the sales channel have certain advantages in terms of market demand and trend judgment. In terms of product selection, Kyushu Tong will focus on the efforts of household products and sensor products. First of all, the full -quality category of household products is achieved, including health monitoring, nasal respiratory, rehabilitation care, mobile auxiliary tools, home use, home use, home use, households, and home use Consumption category. At the same time, the company focuses on anti -sensing control products applied in the operating room. The second is to provide rehabilitation solutions for the hospital's nerves, orthopedics and other departments. From the perspective of market prospects, as the current domestic medical device market has become the "Red Sea" market, Kyushu Tong has chosen to follow the development route of differentiated products to avoid excessive competition. In terms of surgical sensing consumables, in recent years, domestic stable medical care, Zhende Medical and other enterprises have also been deployed. At present, the overall scale is yet to be broken. According to statistics from the CMI agency, the domestic market size of the operating room infection control products is expected to reach 3.688 billion US dollars in 2026, with an average annual compound growth rate of 4.9%. At the same time, the scale of my country's customized surgical combination package is expected to rise to 1.504 billion US dollars, with an average annual compound growth rate of 12.2%, and the market prospects are relatively broad.

Rong Wenhui believes that "the popularity of one -time surgery consumables in foreign countries has reached more than 90%, and only about 10%of the domestic. There is a certain imagination space, but it is still in its infancy and it should continue to volume. In terms of rehabilitation, with the reform of national medical insurance and payment methods, the patient's hospitalization time will be shortened, and it will turn to the rehabilitation department after surgery. The market size of Yuan, but there is no head -of -head enterprise at present, and the manufacturers are more scattered. "

Further adjustment of talents and mechanisms

Furthermore, the products of each sector need to launch different "play", especially in terms of sensory control and rehabilitation. Enterprises in the field in this field need to first complete market cultivation. Rong Wenhui said, "Sensor products need to be promoted in large benchmarks and communicate with the operating room-related medical workers. According to calculations, anti-sensing control products can first save the cost of hospitals, and the cost will be 10%-20 cheaper 10%-20 %. At the same time, it also has convenience. Because the expenditure in this area is included in the hospital cost, it is a procurement behavior, and there is a certain difficulty in promoting. Rehabilitation also needs to cultivate consumers' awareness and determine the market trend through demand. "

In addition, Kyushu Tong chose to create an independent brand in the past three years. The scale of independent brand products is about 100 million yuan. The brand recognition has a lot of room for improvement. Brand cognition is more important. At the beginning of 2021, Kyushu Tong released the "Wandian Alliance Plan". As of the end of 2021, 6,138 self -employment and franchise pharmacies have been achieved, covering 28 provinces and cities across the country. It is expected that it will exceed 10,000 at the end of 2022. It is expected to reach 3 in the next 3 years. Wanjia, the number of members of the C -end of the C -side exceeds 100 million people. In terms of production layout, while the company is mainly OEM, the target of rehabilitation and home tracks is also paying attention to the factory in the factory of OEM. For large -scale high -consumable companies, the company will enter the market in the form of participation and strengthen strategic cooperation.

Judging from the current dynamics of medical business head enterprises, the transformation layout of Kyushu Tong is relatively rapid, and other industry companies also have the strength to transform into this industry. In 2021, through deepening cooperation with leading industry partners, the related products manufactured by Chinese Medicine Holdings have gradually extended from more than 100 medical consumables to medical device categories with high -tech barriers with high -tech barriers. Sinopharm Holdings also said that Chinese Medicine Holdings conforms to the development trend of domesticization, seek the establishment and promotion of independent brands, and steadily build the service capabilities of the "life cycle" of the device business covering the product.

The advantages of products to build require the corporate management mechanism and talent organization capabilities. In the business sector business, the channels of Kyushu Tong have restricted the company's gross profit level to a certain extent. "But the company's cost management is good, and the mechanism and control are relatively flexible." Rong Wenhui believes that in refined management, Kyushu has an advantage.

"But the strategy of transforming medical devices has certain challenges. Industry and services still need to clearly develop development models. The company is still being explored and needs to constantly correct the development path." Rong Wenhui also said that the company needs to introduce talents to do products and talents for talents. The professional requirements will be stricter. While understanding market demand, it is necessary to have a comprehensive grasp of product design, various surgical, and disease knowledge. On this basis, enterprises in the industry's new business sector in the industry also need to be improved in terms of organizational structure and management concepts.

- END -